Setback for AstraZeneca as Breast Cancer Drug Misses Key Trial Goal
What Happened
AstraZeneca's breast cancer drug Etcamah (camizestrant) failed to achieve the primary goal of improving progression-free survival in the late-stage SERENA-4 trial. The drug was tested in combination with palbociclib (Ibrance) in previously untreated patients with advanced hormone-driven breast cancer. While the combination showed a numerical improvement, it was not statistically significant.
Key Takeaways
The result is a setback for AstraZeneca's plans to expand Etcamah's use in a broader group of breast cancer patients, though the drug remains approved in several markets for patients with specific ESR1 mutations. Analysts described the outcome as disappointing but not a major blow to the drug's long-term prospects, as other studies and indications remain in play.